Search research articles
Contact Us
Filters
Showing results (511-520 of 703) with videos related to
Page
of 71
Sort By:
JAMA Oncology
|
December 4, 2015
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B Johnson, Ryan J Sullivan, Patrick A Ott, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 24, 2018
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study
Sara Valpione, Matteo S Carlino, Johanna Mangana, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2018
Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]
Sara Valpione, Matteo S Carlino, Johanna Mangana, et al.
The Lancet. Oncology
|
February 16, 2026
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study
Reinhard Dummer, Jun Guo, Jason J Luke, et al.
The New England Journal of Medicine
|
October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Keith T Flaherty, Jeffery R Infante, Adil Daud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2024
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study
Jason J Luke, Paolo A Ascierto, Muhammad A Khattak, et al.
The New England Journal of Medicine
|
January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.
Nature Cancer
|
February 5, 2022
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma
Lisa Haas, Anais Elewaut, Camille L Gerard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 1, 2016
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A M Menzies, D B Johnson, S Ramanujam, et al.
Oncoimmunology
|
February 5, 2019
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients
Hansol Lee, Camelia Quek, Ines Silva, et al.
Page
of 71
Search research articles
Search
Showing results (511-520 of 703) with videos related to
Sort By:
Page
of 71
JAMA Oncology
|
December 4, 2015
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B Johnson, Ryan J Sullivan, Patrick A Ott, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 24, 2018
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study
Sara Valpione, Matteo S Carlino, Johanna Mangana, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2018
Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]
Sara Valpione, Matteo S Carlino, Johanna Mangana, et al.
The Lancet. Oncology
|
February 16, 2026
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study
Reinhard Dummer, Jun Guo, Jason J Luke, et al.
The New England Journal of Medicine
|
October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Keith T Flaherty, Jeffery R Infante, Adil Daud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2024
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study
Jason J Luke, Paolo A Ascierto, Muhammad A Khattak, et al.
The New England Journal of Medicine
|
January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.
Nature Cancer
|
February 5, 2022
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma
Lisa Haas, Anais Elewaut, Camille L Gerard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 1, 2016
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A M Menzies, D B Johnson, S Ramanujam, et al.
Oncoimmunology
|
February 5, 2019
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients
Hansol Lee, Camelia Quek, Ines Silva, et al.
Page
of 71